

Date: 23-01-2025

To,
National Pharmaceutical Regulatory Agency
Lot 36, Jalan University, 46200,
Petaling Jaya, Selangor,
Malaysia

Subject: Commitment for D4

Product Name: Seroflo Inhaler 125 (Registration No: MAL07090897AZ) and Seroflo Inhaler 250 (Registration No: MAL07090898AZ)

Respected Sir/Madam,

We hereby commit to submit updated D4 in next variation for PI. We are requesting NPRA to review the submitted package based on this commitment.

Pls consider.

Thank you
For Cipla Limited


Sheetal More
Senior Manager, Regulatory Affairs

